Fulcrum’s Losmapimod Improves Multiple Measures, But Not Primary Endpoint

Secondary Endpoints May Matter More In FSHD Study

 
• By Alaric DeArment

The ReDUX4 study missed its biomarker-driven primary endpoint, making it unclear if an additional trial will be needed for regulatory submission.

MUSCULAR DYSTROPHY words written on label tag with medicine,syringe,keyboard and stethoscope
Fulcrum presented data from the Phase IIb study of losmapimod in FSHD • Source: Shutterstock

More from Rare Diseases

More from Scrip